• SOSV Investments LLC analysis of a therapeutics virtual matchmaking event tracked 571 founders and investors, generating more than 1,000 meetings.
• Investor and startup focus aligned on major disease areas, led by oncology, immunology and inflammation, neurology and CNS.
• Modality preferences diverged; RNA therapeutics ranked high for investors but represented 12% of startups, while drug delivery skewed toward startups.
• Platform-heavy participation signaled investor demand; 42% of startups paired a platform with an internal pipeline, versus 84% investor interest.
• AI adoption was widespread at 52% of startups; 57% of investors indicated willingness to lead deals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SOSV Investments LLC published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.